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89* Moli1901 (duramycin) increases chloride transport in
cystic ﬁbrosis airway epithelial and pancreatic cell lines
I. Oliynyk1,2, G. Varelogianni2, G.M. Roomans2, M. Johannesson1. 1CF-center,
Academic Hospital, Uppsala, Sweden; 2Medical Cell Biology, Uppsala University,
Uppsala, Sweden
The lantibiotic Moli1901 is a polycyclic peptide derived from Streptomyces cinna-
moneum, which has been reported to stimulate chloride (Cl−) efﬂux from airway
epithelial cells, and therefore it has been suggested as a potential drug for the
treatment of cystic ﬁbrosis (CF).
In the present study, we investigated the effect of Moli1901 on Cl− efﬂux from
normal human bronchial epithelial (16HBE) cells, a CF airway epithelial (CFBE)
cell line, a normal pancreatic epithelial cell line (PANC-1), a CF pancreatic
cell line (CFPAC-1), normal human airway submucosal gland cells (Calu-3), CF
airway submucosal gland cells (CFSME), and untransfected baby hamster kidney
ﬁbroblasts (BHK-wt).
Cl− efﬂux was determined with the help of a ﬂuorescent probe, N-(ethoxycarbonyl-
methyl)-6-methoxyquinolinium bromide (MQAE).
It was found that Moli1901 dissolved in Standard Ringer’s solution without Cl− ions
(SR0) signiﬁcantly stimulated Cl− efﬂux from CFBE cells (at a concentration of
1mM), from CFPAC cells (at 3mM) and from Calu-3 cells (at 1 and 10mM). In these
cells, stimulated Cl− efﬂux was signiﬁcantly increased over basal Cl− efﬂux, and
a stimulation corresponding to 30−40% of wild-type CFTR activity was obtained.
Further experiments in the presence of inhibitors of CFTR (inhibitor-172), of Ca2+-
activated Cl− channels (gadolinium), and of the calcium ionophore A23187 were
performed.
These results show that Moli1901 causes a CFTR-independent Cl− efﬂux, which
may explain the beneﬁcial action of Moli1901 on FEV1, recently documented in a
short-term clinical trial (Chest 131:4161; 2007).
Supported by: Swedish Association for Cystic Fibrosis, the Swedish Heart-Lung
Foundation and the Swedish Science Research Council.
90* Safety, tolerability and efﬁcacy of multiple doses of aerosolised
Moli1901 in adolescents and adults with cystic ﬁbrosis
E. Eber1, H. Grasemann2, G.H. Thalhammer1, R. Widmann3, F. Ratjen2.
1Paediatric Department, Medical University of Graz, Graz, Austria; 2Division
of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada;
3AOP Orphan Pharmaceuticals AG, Vienna, Austria
Moli1901 activates a Ca2+-dependent alternative Cl− channel with the potential to
compensate for CFTR deﬁciency.
Two phase II randomised, placebo-controlled, double-blinded studies were per-
formed in CF patients with stable lung disease and a FEV1 >60% predicted.
A multiple (5 days), rising-dose (0.5, 1.5, or 2.5mg/d of Moli1901) study was
conducted in 24 patients 16 yrs (I) (Grasemann H et al., Chest 2007). In a second
study, 2.5mg/d Moli1901 or placebo were administered once daily for 28 days in 18
patients (9 16, and 9 12 yrs) (II). Over periods of 4 (I) and 8 (II) wks, adverse
events (AEs), spirometry, pulse oximetry and quality of life were assessed.
In I, Moli1901 was well tolerated in all but 2 patients (1: transient signiﬁcant
decrease in FEV1 following inhalation which resolved spontaneously, treatment
discontinued; 2: transient throat numbness during inhalation). In II, no signiﬁcant
AE was observed; the most frequent AEs were cough and dry throat, most of
them resolved within 1 hour after inhalation. Both trials were not designed to show
efﬁcacy; however, a signiﬁcant difference in the median change in FEV1 from day 1
to day 5 was observed between the 2.5mg/d Moli1901 and the placebo group in I
(p = 0.01), and in the median change in FEV1 from day 1 to day 56 between the
Moli1901 and placebo group in II (p = 0.02).
Moli was well tolerated in both trials, and appears to be safe in adolescent and adult
CF patients. In addition, Moli1901 had a beneﬁcial effect on pulmonary function,
which supports further investigation of its efﬁcacy.
Supported by AOP Orphan Pharmaceuticals AG, Vienna, Austria.
91* Preventive but not late amiloride therapy reduces morbidity and
mortality of cystic ﬁbrosis-like lung disease in mice
D. Treis1, Z. Zhou1, S. Schubert1, M. Harm1, J. Schatterny1, S. Hirtz1, J. Duerr1,
R.C. Boucher2, M.A. Mall1. 1Ped. Pulmonology and CF Center, Dept. of
Pediatrics III, University of Heidelberg, Heidelberg, Germany; 2CF Center, School
of Medicine, University of North Carolina, Chapel Hill, NC, USA
Increased airway Na+ absorption is a characteristic abnormality in the pathogenesis
of cystic ﬁbrosis (CF) lung disease. We previously demonstrated that mimicking
accelerated Na+ transport in mice by airway-speciﬁc overexpression of epithelial
Na+ channels (ENaC) caused dehydration of airway surfaces, deﬁcient mucus
clearance, and a spontaneous lung disease sharing key features with CF in humans.
In the present study, we used bENaC-transgenic (bENaC-Tg) mice to test if inhi-
bition of increased Na+ absorption by the ENaC blocker amiloride has therapeutic
effects on CF-like lung disease in vivo. bENaC-Tg and wild-type mice were
treated by intranasal instillation of amiloride or vehicle for a period of 14 days.
Subsequently, mice were killed, bronchoalveolar lavage (BAL) performed, and lungs
processed for histology. We show that early amiloride treatment, i.e., from the ﬁrst
day of life, signiﬁcantly reduced pulmonary mortality, airway mucus obstruction,
and airway inﬂammation in bENaC-Tg mice. In contrast, consistent with previous
human trials in CF patients, amiloride did not have beneﬁts if treatment was started
after the development of CF-like lung disease in bENaC-Tg mice.
We conclude that preventive inhibition of increased airway Na+ absorption provides
an effective therapy for CF-like lung disease in vivo. These results suggest that
ENaC blocker treatment may be an effective preventive therapy for patients with CF
if initiated early in life prior to the onset of lung disease.
Supported by: CFF (MALL04G0) and EC (MEXT-2004–013666).
92 Duration of decreasing the nasal potential difference by
amiloride–mannitol dry powder
D. Schu¨ler1, S. Luigart1, S. Prange-Schmidt1, C. Geidel1, K.P. Zimmer1, J. Pabst2,
H. Lindemann1. 1CF-Centre, University hospital, Giessen, Germany; 2Ho¨chstadt,
Donau, Germany
Hyperabsorption of sodium and subsequent water loss are believed to account
for high sputum viscoelasticity in cystic ﬁbrosis (CF). Problems were the time
consuming inhalation of amiloride solution and a limited duration of the sodium
blocking effect. Therefore the duration of an innovative amiloride/mannitol dry
powder formulation administered in the nasal cavity was examined with nasal
potential difference measurement (nPD).
In 7 CF patients (15 to 42 years) and 15 healthy persons (21 to 36 years)
the acting of nPD-changing before and after nasal administration of amiloride/
mannitol dry powder was examined. Basal nPD was measured subcutaneously in
CF patients and controls. Then amiloride/mannitol dry powder was administered
(composition: 1mg amiloride//24mg mannitol) nasally via an Aerolizer. 5 minutes
after insufﬂation the nPD was recorded again and the duration of nPD-decrease was
determined. The half-time-value was deﬁned by the time until the nPD reached 50%
of basal nPD.
The study was approved by the ethical committee of the University of Giessen.
In 7 CF patients the nPD decreased about 74±11%. The max. nPD decrease was
reached after 27±19 minutes. The time until the nPD reached 50% of basal nPD
was reached after 137±52 minutes.
In 15 healthy controls the max. nPD-decrease amounted 75±14% and was reached
after 44±31 minutes. The time until nPD reached 50% of basal nPD was 106±44
minutes.
Amiloride/mannitol dry powder is effective and decreases the nasal potential
difference until 75% of basal nPD in CF patients and healthy controls. The duration
of decreasing is between 1.5 to 2 hours. The new innovative amiloride/mannitol dry
powder formulation seems to be more practicable and saves time.
